MedTrace Logo

Prevention of Atrial Fibrillation Following Esophagectomy

NCT00420017 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2013-09-18

Study results available
· View outcomes & findings →

Summary

The investigators hypothesize that the medication amiodarone decreases the incidence of atrial fibrillation (AF) following esophagectomy surgery. Their specific aims are to:

Determine the effectiveness of amiodarone for the prevention of AF following esophagectomy surgery; Determine the influence of the prevention of AF following esophagectomy surgery on post-surgical duration of stay in the Intensive Care Unit ICU)and duration of post-surgical hospital stay; and Determine the safety of amiodarone for the prevention of AF following esophagectomy surgery.

Conditions

Interventions

DRUG

Amiodarone

Intravenous amiodarone continuous infusion x 4 days

OTHER

Control

No amiodarone

Sponsors & Collaborators

  • Purdue University

    collaborator OTHER

  • Indiana University Health

    collaborator OTHER

  • Indiana University

    lead OTHER

Principal Investigators

  • James E Tisdale, PharmD · Purdue University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00420017 on ClinicalTrials.gov